VEGFR2/KDR/Flk1 Cancer Research Results

VEGFR2/KDR/Flk1, Vascular Endothelial Growth Factor Receptor 2: Click to Expand ⟱
Source:
Type: receptor tyrosine kinase
VEGFR2; human gene symbol KDR; also called Flk-1 or CD309) is a receptor tyrosine kinase that plays a crucial role in angiogenesis, the process of new blood vessel formation. In cancer, VEGFR2 is often overexpressed, promoting the growth of new blood vessels that supply the tumor with oxygen and nutrients, facilitating its growth and metastasis.
Inhibiting VEGFR2 signaling has been shown to be an effective strategy in cancer therapy, and several VEGFR2 inhibitors have been approved for the treatment of various types of cancer, including renal cell carcinoma, colorectal cancer, and non-small cell lung cancer. These inhibitors work by blocking the binding of VEGF to VEGFR2, thereby inhibiting angiogenesis and tumor growth.
Scientific Papers found: Click to Expand⟱
7990- itraC,    A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial
- Trial, Ovarian, NA
Dose↝, itraconazole group received six chemotherapy cycles and 400 mg oral itraconazole for five days per cycle.
DCR↑, The objective response rate was 80% in the itraconazole group compared with 47% in the placebo group (p = 0.015), while the disease control rate was 100% versus 80%, respectively (p = 0.023).
PFS↑, Progression-free survival was significantly improved in the itraconazole group, with 70% of patients remaining progression-free compared with 26.7% in the placebo group
CA125↓, itraconazole group produced significant declines in the serum levels of CA-125 (p = 0.005) and p-glycoprotein (p = 0.042) with significant elevation in VEGFR-2 (p = 0.006) as compared to the control group.
P-gp/ABCB1↓,
VEGFR2/KDR/Flk1↑,
toxicity↓, Itraconazole was safe and its use was associated with a significant improvement in the quality of life (QOL).
QoL↑,
toxicity↝, no significant variations observed between the two study groups in the terms of reported adverse effect of the treatment including hematological toxicity such as anemia, neutropenia, thrombocytopenia, and non-hematological toxicity such as nausea, di

3482- MF,    Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice
- in-vitro, NA, NA
*cardioP↑, PEMF treatment with 30 Hz 3.0 mT significantly improved heart function.
*VEGF↑, PEMF treatment with 15 Hz 1.5 mT and 30 Hz 3.0 mT both increased capillary density, decreased infarction area size, increased the protein expression of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 2 (VEGFR2
*VEGFR2/KDR/Flk1↑,
*Hif1a↑, and increased the mRNA level of VEGF and hypoxia inducible factor 1-alpha (HIF-1α) in the infarct border zone.
*FGF↑, Additionally, treatment with 30 Hz 3.0 mT also increased protein and mRNA level of fibroblast growth factor 2 (FGF2), and protein level of β1 integrin, and shows a stronger therapeutic effect.
*ITGB1↑,
*angioG↑, PEMFs Improve Angiogenesis In Vivo


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

DCR↑, 1,   PFS↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGFR2/KDR/Flk1↑, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CA125↓, 1,  

Functional Outcomes(tgid=23) ⓘ

QoL↑, 1,   toxicity↓, 1,   toxicity↝, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Proliferation, Differentiation & Cell State(tgid=12) ⓘ

FGF↑, 1,  

Migration(tgid=13) ⓘ

ITGB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,   Hif1a↑, 1,   VEGF↑, 1,   VEGFR2/KDR/Flk1↑, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,  
Total Targets: 7

Scientific Paper Hit Count for: VEGFR2/KDR/Flk1, Vascular Endothelial Growth Factor Receptor 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:768  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page